Lilly Licenses Ascidian RNA Rxon-Editing Platform for Inherited Kidney Diseases

Eli Lilly has licensed Ascidian Therapeutics’ RNA exon-editing technology for undisclosed rare inherited kidney disease targets in a transaction valued at up to $1.9 billion, according to Reuters.¹ The agreement adds another preclinical genetic medicine platform to Lilly’s pipeline strategy, but it does not yet include disclosed drug candidates, clinical trial data, or a regulatory filing.

“We think [Ascidian’s technology] has many of the benefits of a traditional CRISPR or DNA editing technology, but with the key advantage of not actually altering the patient’s DNA, only changing RNA,” Daniel Rosan, chief business officer of Ascidian, told Reuters.¹ Clinically, the distinction is relevant because many inherited kidney disorders are monogenic or strongly genetically mediated, yet the field still faces substantial delivery, durability, safety, and target-selection challenges before RNA-editing approaches can be evaluated as disease-modifying therapies.

What did Lilly license from Ascidian?

Under the agreement, Lilly will receive exclusive rights to apply Ascidian’s RNA exon-editing platform to certain undisclosed kidney disease targets. Ascidian is eligible to receive up to $1.9 billion, including an undisclosed upfront payment, development, regulatory, and sales milestones, and royalties on future product sales.¹

Ascidian will lead early research and some preclinical activities, while Lilly will be responsible for later-stage development, manufacturing, and commercialization. Lilly may add additional targets under the collaboration, while Ascidian retains rights to pursue other kidney disease programs outside the Lilly agreement.¹

The deal is not tied to a named clinical trial or regulatory submission. No patient population, dosing strategy, delivery system, efficacy endpoint, or safety dataset was disclosed. As a result, the near-term significance is primarily platform and pipeline related rather than practice changing.

Reuters reported that Lilly has recently expanded its genetic medicine activities through several transactions, including its acquisition of Verve Therapeutics and collaborations with Profluent and Seamless Therapeutics.¹ Ascidian previously licensed its technology to Roche in 2024 for difficult-to-treat neurologic diseases.¹

How could RNA exon editing fit kidney disease?

Inherited kidney diseases represent a heterogeneous group of disorders that can progress to chronic kidney disease, kidney failure, or need for kidney replacement therapy. Genomic diagnosis is increasingly important in nephrology; in a large exome-sequencing study of patients with kidney disease, Groopman and colleagues reported diagnostic findings across a range of renal phenotypes, supporting the clinical relevance of genetic mechanisms in nephrology.²

Current chronic kidney disease management emphasizes diagnosis of cause, risk stratification, blood pressure control, renin-angiotensin system inhibition when appropriate, sodium-glucose cotransporter 2 inhibitor use in eligible patients, and management of complications, according to KDIGO guidance.³ For many rare inherited kidney diseases, however, treatment remains supportive or disease specific, and options capable of correcting the underlying molecular defect are limited.

Ascidian’s platform is described as RNA exon editing, designed to correct faulty gene expression at the RNA level without permanently altering genomic DNA.¹ That differentiates it conceptually from DNA-directed CRISPR editing, which uses programmable nucleases to modify DNA sequences. Genome-editing technologies have advanced rapidly, although investigators continue to evaluate issues including off-target effects, delivery challenges, and long-term safety considerations.⁴

For kidney disease, tissue delivery is likely to be a central translational issue. The kidney contains multiple specialized cell types, including podocytes, tubular epithelial cells, endothelial cells, and collecting duct cells, and the relevant target cell differs by disease. A platform that edits RNA rather than DNA may offer theoretical safety advantages, but those advantages remain to be demonstrated in renal tissue and in patients.

What questions remain before clinical development?

The collaboration leaves several key scientific and clinical questions unanswered. Lilly and Ascidian did not identify the kidney disease targets, whether the programs are intended for glomerular, tubular, ciliopathy-related, complement-mediated, or other inherited disorders, or whether the delivery approach will use viral, lipid nanoparticle, conjugate, or another modality.¹

No preclinical efficacy or toxicology data were included in the Reuters report. Without those data, it is not possible to assess editing efficiency, tissue specificity, duration of RNA correction, immunogenicity, dose-response characteristics, or potential class-specific safety signals. Similarly, because no clinical candidates were named, there is no basis yet to compare the approach with approved or investigational therapies in any specific rare kidney disease.

The collaboration may nevertheless reflect continued industry interest in genetic medicines for diseases with clearly defined molecular drivers. Michael Ehlers, chief executive officer of Ascidian, said the companies aim to “dramatically reduce the burden of genetic kidney disease.”¹ For now, that aim remains an early research objective. The next meaningful milestones will be disclosure of targets, preclinical proof-of-concept data, candidate selection, and eventual investigational new drug–enabling studies.

References

1. Reuters. Lilly gains license for Ascidian's gene-editing tech to develop kidney disease drugs. Published June 3, 2026. https://www.reuters.com/legal/litigation/lilly-gains-license-ascidians-gene-editing-tech-develop-kidney-disease-drugs-2026-06-03
2. Groopman EE, Marasa M, Cameron-Christie S, et al. (2018 Dec 26). Diagnostic utility of exome sequencing for kidney disease. N Engl J Med. https://www.nejm.org/doi/full/10.1056/NEJMoa1806891
3. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. (2024). KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. https://kdigo.org/guidelines/
4. Anzalone AV, Koblan LW, Liu DR. (2020 Jun 22). Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat Biotechnol. https://pubmed.ncbi.nlm.nih.gov/32572269/